Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

By Chang-Qi Zhu, G. da Cunha Santos, K. Ding, A. Sakurada, J. Cutz, Ni Liu, Tong Zhang, P. Marrano, M. Whitehead, J. Squire and 4 more. Journal of Clinical Oncology, 2008

718 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/215dbf9ded44443a19ad70f719065f3faf87d146

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Batra
2. A. Ganti
3. Maneesh Jain
4. M. Ponnusamy
5. D. Haridas
6. P. Seshacharyulu

Citations in the corpus

• Targeting the EGFR signaling pathway in cancer therapy (2012, background): “Recent studies evaluating EGFR TKIs in patients with these activating EGFR gene mutations demonstrated a consistent improvement in progression-free survival, but none of these trials have demonstrated an improvement in overall survival [126-128].”